Track record as reliable nebulizer manufacturer

Track Record

As our partner –

you mitigate your device-associated risk.

Five drug and device combination products with eFlow® Technology nebulizers have been approved by regulatory authorities in North America, Europe, and Japan

  • More than 20 years of experience in membrane nebulizer development & commercialization
  • Strong interest in long-term sustainable business and partnerships
  • Regulatory authorities are familiar and comfortable with eFlow® Technology nebulizers
Timeline Committed partnership
  • Cayston® (Gilead Sciences Inc., administered via the Altera® nebulizer, approved in the US, EU and Canada)  www.cayston.com
  • ColiFin®/Colfinair® (PARI Pharma GmbH, administered via an eFlow®rapid nebulizer handset, approved in the EU)  www.pari.com/colifin
  • QUINSAIR™ (Horizon, administered via the Zirela® nebulizer, approved in the EU and Canada)  www.horizonpharma.com
  • Vantobra® (PARI Pharma GmbH, administered via the Tolero® nebulizer handset, approved in the EU)  www.pari.com/vantobra
  • ARIKAYCE® (Insmed Incorporated, administered via the Lamira® Nebulizer System, approved in the US, EU and Japan)  www.arikayce.com
Lamira for Arikayce

Lamira®

The Lamira nebulizer handset with an eBase® Controller is intended to administer ARIKAYCE® as an aerosol for inhalation.

Lamira is an eFlow® Open System Nebulizer.
More information

ARIKAYCE is marketed in the US, EU, and Japan by Insmed, a global biopharmaceutical company headquartered in the United States.

For additional information please refer to the package leaflet of the medicinal product.

Further information:
www.insmed.com
www.arikayce.com
News release FDA approval
News release European Commission approval
News release Japan's Ministry of Health approval

Zirela for Quinsair

Zirela®

The Zirela nebulizer handset with an eBase® Controller is intended to administer QuinsairTM as an aerosol for inhalation.

Zirela is an eFlow® Open System Nebulizer.
More information

Quinsair 240 mg nebulizer solution is marketed in the EU (MAH: Chiesi Limited) and Canada (MAH: Horizon).

For additional information please refer to the package leaflet of the medicinal product.

Further information:
www.horizonpharma.com
https://globenewswire.com/news-release

Tolero for Vantobra

Tolero®

The Tolero nebulizer handset with an eBase® or eTrack® Controller is intended to administer Vantobra® as an aerosol for inhalation.

Tolero is an eFlow® Open System Nebulizer.
More information

Vantobra 170 mg nebulizer solution was developed by PARI Pharma GmbH and is marketed in several EU countries (MAH: PARI Pharma GmbH) and in Switzerland (MAH: PARI Swiss AG). Each package of Vantobra provides the patient with a new Tolero nebulizer handset.

For additional information please refer to the package leaflet of the medicinal product.

Further information:
www.pari.com/vantobra-de/home [German page]

eFlow rapid

eFlow®rapid

The eFlow®rapid nebulizer handset with an eBase® Controller is intended to administer nebulizer solutions or suspensions as an aerosol for inhalation approved for the treatment of diseases of the lower airways. For example, ColiFin® / Colfinair®, a product of PARI Pharma.

eFlow®rapid is an Open System Nebulizer.
More information

Each package of ColiFin / Colfinair contains saline solution for reconstitution and a new eFlow®rapid nebulizer handset. Because of this unique selling proposition, the specific drug and device concept, marketed in several countries in the EU, is highly accepted.

For additional information please refer to the package leaflet of the medicinal product.

Further information:
www.pari.com/colifin-de/home [German page]
www.pari.com/colifin-at/home [Austrian page]
www.pari.com/colifin-es [Spanish page]

Altera for Cayston

Altera®

The Altera nebulizer handset with an eBase® Controller is intended to administer Cayston® as an aerosol for inhalation.

Altera is an eFlow® Open System Nebulizer.
More information

Cayston 75 mg powder and solvent for nebulizer solution is marketed by Gilead Sciences in the US, EU, and Canada.

For additional information please refer to the package leaflet of the medicinal product.

Further information:
www.cayston.com

ARIKAYCE is a registered trademark of Insmed Incorporated
Cayston® is a registered trademark of Gilead Sciences Inc.
QUINSAIR™ is a trademark of Horizon
eFlow®, eBase®, eLete®, eTrack®, ePort®, eRapid®, Altera®, Zirela®, Tolero®, Lamira®, Vantobra®, ColiFin®, Colfinair® are registered trademarks of PARI Pharma GmbH

eFlow Technology nebulizers with digital therapy management: The PARI Connect eco-system

eFlow Technology nebulizers with digital therapy management

Learn how the PARI Connect system supports patients with carefully considered device usability and digital therapy management solutions.
 

Read more

Your innovative aerosol therapy – our drug-nebulizer expertise

YOUR innovative aerosol therapy – OUR drug-nebulizer expertise

Watch five short expert interviews containing all you need to know about our partnering approach for pharmaceutical companies.
 

Read more

Developing new drug-nebulizer combination products

Developing new drug-nebulizer combination products

Learn more about the critical success factors and opportunities for bringing a new vibrating membrane nebulizer as a drug-device combination product to the market.

Read more

Contact us

Do you have any questions about our technology, partnering approach and services?

Please contact us!
eFlow-partneringpari.com

 

PARI Germany